VERAXA Biotech (NASDAQ: VRXA) announced today that its bispecific antibody-drug conjugate (bsADC) program, VXA-222, has reached a key technical milestone under its collaboration with OmniAb. OmniAb has successfully completed its discovery work, allowing the program to move into the next phase of development. VXA-222 is designed to target two tumor antigens using an "AND-gate" approach, which aims to improve precision in treating solid tumors by requiring simultaneous binding to both targets for activation.
The collaboration, launched in May 2025, leverages OmniAb’s antibody discovery technologies, including its OmniClic platform, while VERAXA applies its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. Under the terms, VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue from resulting products.
VERAXA is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs. The company’s BiTAC format and other innovative approaches are guided by quality-by-design principles, aiming to advance candidates into clinical development. VERAXA was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL).
The full press release is available at https://ibn.fm/qMRuJ. For the latest news and updates on VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
This announcement underscores progress in the bispecific ADC field, potentially offering more targeted therapies for solid tumors. The advancement of VXA-222 could represent a step forward in precision oncology, though further clinical validation is needed.
